GLP-1 RAs & Bone/Joint Risks: Osteoporosis, Gout & Osteomalacia Study

New research presented this week at the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) in New Orleans suggests a potential long-term risk associated with the increasingly popular glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including medications like semaglutide. The study indicates that treatment with these drugs, commonly prescribed for type 2 diabetes and obesity, may be linked to a significantly increased five-year risk of osteoporosis, gout and osteomalacia compared to individuals who do not use them.

Understanding GLP-1 Receptor Agonists and Their Rise

GLP-1 RAs have gained widespread attention for their effectiveness in managing blood sugar levels, promoting weight loss, and reducing cardiometabolic risks. This has led to a rapid increase in their use among patients with both obesity and type 2 diabetes. However, as with any medication, understanding the potential long-term effects is crucial. The AAOS meeting highlighted emerging research focused on the impact of these drugs on musculoskeletal health, an area where data has been relatively limited until recently.

Osteoporosis is a condition characterized by weakened bones, increasing the risk of fractures. Gout is a form of inflammatory arthritis caused by a buildup of uric acid crystals in the joints. Osteomalacia, often referred to as rickets in children, involves softening of the bones due to vitamin D deficiency or impaired bone mineralization. These conditions can significantly impact quality of life, and mobility.

The Study: Design and Key Findings

The research, led by Muaaz Wajahath, a medical student at Michigan State University College of Human Medicine, examined the association between GLP-1 RA use and the incidence of these three musculoskeletal conditions. The study presented at the AAOS meeting is reaching the point where five- and ten-year follow-up data are becoming available for patients taking these medications, allowing for a more comprehensive assessment of long-term effects. While the specific details of the study design – including sample size and methodology – weren’t immediately available in the provided sources, the findings suggest a statistically significant increase in risk among GLP-1 RA users.

Researchers emphasize that this rapid adoption of GLP-1 RAs necessitates close examination, particularly within orthopaedics, where obesity and surgical interventions are common. The long-term effects of these medications on bone and joint health remain an area of ongoing investigation. Further details about the study can be found in a press release from the American Academy of Orthopaedic Surgeons.

Postoperative Benefits Alongside Potential Risks

Interestingly, the research similarly indicated a potential benefit of GLP-1 RA use in the short-term postoperative period following orthopaedic surgery. Researchers are exploring whether these medications can improve recovery rates after procedures. Haroun Haque, a medical student at SUNY Downstate College of Medicine, noted that there has been limited research on the impact of GLP-1 use on postoperative outcomes, highlighting the need for further investigation in this area. This suggests a complex interplay between the benefits and potential risks of GLP-1 RAs, requiring a nuanced understanding for both patients and clinicians.

What Does This Mean for Patients?

It’s important to emphasize that this research demonstrates an association, not necessarily a direct causation. The study suggests a link between GLP-1 RA use and increased risk, but it doesn’t definitively prove that the medications cause these conditions. Other factors, such as underlying health conditions, lifestyle choices, and genetics, could also play a role.

Patients currently taking GLP-1 RAs should not stop their medication without consulting with their healthcare provider. Discontinuing medication abruptly can have negative consequences for blood sugar control and overall health. Instead, individuals should discuss these findings with their doctor to assess their individual risk factors and determine the best course of action. The Drugs.com report on the AAOS findings underscores the importance of this conversation.

Risk Context: Separating Relative from Absolute Risk

Understanding the magnitude of the increased risk is also crucial. The study highlights a “significantly increased” risk, but it’s important to consider both relative and absolute risk. Relative risk refers to the increase in risk compared to non-users, while absolute risk represents the actual probability of developing the condition. For example, a doubling of risk (a relative risk of 2) may sound alarming, but if the baseline risk is very low, the absolute increase in risk may still be compact. Without specific data on absolute risk from the study, it’s difficult to fully assess the clinical significance of these findings.

The Evolving Landscape of GLP-1 RA Research

The findings presented at the AAOS meeting are part of a growing body of research examining the long-term effects of GLP-1 RAs. As more data develop into available, a clearer picture will emerge regarding the benefits and risks of these medications. Researchers are actively investigating the mechanisms by which GLP-1 RAs may affect bone and joint health, which could lead to strategies for mitigating potential risks. The American Academy of Orthopaedic Surgeons is committed to disseminating these findings to the medical community and the public. A press release from PR Newswire details the research presented at the 2026 AAOS meeting.

What Comes Next: Surveillance and Guidance Updates

The presentation of these findings at the AAOS meeting is likely to prompt further investigation and potential updates to clinical guidance. Regulatory agencies, such as the Food and Drug Administration (FDA), may review the data and consider whether additional warnings or monitoring are necessary. Healthcare providers will likely incorporate these findings into their discussions with patients, particularly those at higher risk for osteoporosis, gout, or osteomalacia. Ongoing surveillance of musculoskeletal health in patients taking GLP-1 RAs will be essential to track the long-term effects of these medications and inform future clinical practice.